Clarity Pharmaceuticals’ 64Cu-SARTATE Outperforms Standard Imaging in Phase II Trial

Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an update.

Clarity Pharmaceuticals has announced positive results from its Phase II DISCO trial, which evaluated the diagnostic performance of 64Cu-SARTATE in patients with neuroendocrine tumors (NETs). The trial demonstrated that 64Cu-SARTATE is significantly more effective in detecting lesions compared to the standard-of-care imaging agent 68Ga-DOTATATE, with a higher lesion detection rate and sensitivity. The results support the safety and efficacy of 64Cu-SARTATE, prompting Clarity to plan a Phase III study with guidance from the FDA. This advancement could enhance Clarity’s positioning in the radiopharmaceutical industry and offer improved diagnostic options for NET patients.

The most recent analyst rating on (AU:CU6) stock is a Buy with a A$7.40 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes. The company is listed on the Australian Securities Exchange under the ticker CU6 and is dedicated to advancing diagnostic and therapeutic radiopharmaceuticals, particularly in the field of oncology.

Average Trading Volume: 2,894,035

Technical Sentiment Signal: Sell

Current Market Cap: A$609M

Learn more about CU6 stock on TipRanks’ Stock Analysis page.